Beremagene geperpavec-svdt

Krystal Biotech, Priority Review Voucher, Vyjuvek, Beremagene geperpavec-svdt, Rare Pediatric Disease

Krystal Biotech Secures $100 Million in Sale of Priority Review Voucher

Anika Sharma

Krystal Biotech proudly announces the successful transaction of its Rare Pediatric Disease Priority Review Voucher (PRV), yielding an impressive $100 ...